References
- Smith HO, Berwick M, Verschraegen CF, et al. Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol 2006;107:1075–85
- Gershenson DM. Management of ovarian germ cell tumors. J Clin Oncol 2007;25:2938–43
- Lu JH, Gershenson DM. Update on the management of ovarian germ cell tumors. J Reprod Med 2005;50:417–25
- Gershenson DM, Miller AM, Champion VL, et al. Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:2792–97
- Zanetta G, Bonazzi C, Cantù M, et al. Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J Clin Oncol 2001;19:1015–20
- Tangir J, Zelterman D, Ma W, Schwartz PE. Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. Obstet Gynecol 2003;101:251–7
- Ethics Committee of the American Society for Reproductive Medicine. Fertility preservation and reproduction in cancer patients. Fertil Steril 2005;83:1622–8
- Gracia CR, Sammel MD, Freeman E, et al. Impact of cancer therapies on ovarian reserve. Fertil Steril 2012;97:134–40.e1
- Streuli I, Fraisse T, Pillet C, et al. Serum anti-Mullerian hormone levels remain stable throughout the menstrual cycle and after oral and vaginal administration of synthetic sex steroids. Fertil Steril 2008;90:395–400
- Dillon KE, Sammel MD, Prewitt M, et al. Pretreatment anti-Műllerian hormone levels determine rate of post-therapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy. Fertil Steril 2013;99:477–83
- La Marca A, Sighinolfi G, Papaleo E, et al. Prediction of age at menopause from assessment of ovarian reserve may be improved by using body mass index and smoking status. PLoS One 2013;8:e57005
- La Marca A, Papaleo E, Grisendi V, et al. Development of a normogram based on markers of ovarian reserve for the individualization of the follicle-stimulating hormone starting dose in in vitro fertilization cycles. BJOG 2012;119:1171–9
- Ferraretti AP, La Marca A, Fauser BC, et al. ESHRE working group on poor ovarian response definition. Bologna consensus for poor responder. Hum Reprod 2011;26:1616–24
- Mangili G, Sigismondi C, Gadducci A, et al. Outcome and risk factors for recurrence in malignant ovarian germ cell tumors: a MITO-9 retrospective study. Int J Gynecol Cancer 2011;21:1414–21